Trials / Terminated
TerminatedNCT02341209
Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma
Doxycycline in Patients With Relapsed Cutaneous T-cell Lymphoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Rochester General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study looks at the efficacy of Doxycycline for the treatment of Cutaneous T-cell Lymphomas.
Detailed description
The aim of this study is to evaluate the efficacy of doxycycline in relapsed Cutaneous T-cell Lymphomas (CTCL). The primary objective is to determine the overall response rate of doxycycline monotherapy in patients with relapsed CTCL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Doxycycline monohydrate | Doxycycline will be administered in either tablets or capsules for either five months or a year depending on response. |
Timeline
- Start date
- 2018-02-06
- Primary completion
- 2021-02-06
- Completion
- 2021-02-06
- First posted
- 2015-01-19
- Last updated
- 2021-04-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02341209. Inclusion in this directory is not an endorsement.